Skip to content
Peptigraph home

Efinopegdutide Phase 2 trial (NCT05877547)

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
381
actual
Start
23 Jun 2023 (actual)
Primary completion
29 Dec 2025 (actual)
Sponsor
Merck Sharp & Dohme LLC
Design

Arms and doses

NCT05877547 study arms
ArmTypeInterventionsDescription
Efinopegdutide 4mgExperimentalDrug: EfinopegdutideEfinopegdutide administered by subcutaneous (SC) injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks and 4mg for 48 weeks.
Efinopegdutide 7mgExperimentalDrug: EfinopegdutideEfinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, and 7 mg for 44 weeks.
Efinopegdutide 10mgExperimentalDrug: EfinopegdutideEfinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for 40 weeks.
PlaceboPlacebo comparatorDrug: PlaceboPlacebo administered by SC injection once weekly for 52 weeks
Semaglutide 2.4 mgActive comparatorDrug: SemaglutideSemaglutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and 2.4 mg for 36 weeks.
Endpoints

Primary endpoint

NCT05877547 primary outcomes
MeasureTime frame
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52Week 52
Percentage of Participants Who Experienced an Adverse Event (AE)Up to 60 weeks
Percentage of Participants Discontinuing Study Medication Due to an AEUp to 52 weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05877547 secondary outcomes
MeasureTime frame
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52Week 52
Change from Baseline in Body Weight At Week 52Week 52
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic SteatohepatitisClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.